Ann: September 2021 Quarterly Activities Report and Appendix 4C, page-16

Veyonda pricing?

Is there a chance that NOXCOVID if successful, could undermine the price set point for Veyonda if it becames an approved oncology drug?

Here’s an article that talks about pricing a drug during a pandemic and companies being seen to maximize profits. In pricing Veyonda for COVID-19 treatment, it would be hard to then turn around and charge a different price for the same drug in an oncology setting.

https://www.ajmc.com/view/gilead-sciences-sets-us-price-for-covid19-drug-at-2340-to-3120-based-on-insurance

All of this only matters if Veyonda is successful on both fronts but hopefully Noxopharm are able to do the right thing by both potential patients and investors alike.